Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial

Por: Cussac, A, Soberino, J, Gion, M, Bermejo, B, Martinez-Garcia, M, Braga, S, Cardoso, F, Vieira, C, Lopez-Miranda, E, Sampayo, M, Malfettone, A, Cortes, J and Perez-Garcia, J

---

Publicada: 1 sep 2021 Ahead of Print: 1 sep 2021

---

---

Filiaciones:
:
 Hosp Arnau Vilanova, Med Oncol Dept, Valencia, Spain

Soberino, J:
 Inst Oncol IOB Quiron, Med Oncol, Barcelona, Spain

Bermejo, B:
 Univ Valencia, Breast Canc Grp, CIBER ONC ISCIII, Hosp Clin,GEICAM,Biomed Res Inst INCLIVA, Valencia, Spain

Martinez-Garcia, M:
 Hosp Mar, Med Oncol Dept, Barcelona, Spain

Braga, S:
 Inst CUF Oncol, Oncol Dept, Lisbon, Portugal

Cardoso, F:
 Champalimaud Fdn Canc Ctr, Breast Unit, Lisbon, Portugal

Vieira, C:
 Inst Portugues Oncol Porto, Med Oncol Dept, Porto, Portugal

Lopez-Miranda, E:
 Hosp Univ Ramon Cajal, Med Oncol Dept, Madrid, Spain

Sampayo, M:
 Med Scientia Innovat Res Medsir, Dept Sci, Barcelona, Spain

Malfettone, A:
 Med Scientia Innovat Res Medsir, Dept Sci, Barcelona, Spain

Cortes, J:
 VHIO Valle Hebron Inst Oncol, Oncol Dept, Barcelona, Spain

Perez-Garcia, J:
 Int Breast Canc Ctr IBCC, Quiron Grp, Med Oncol Dept, Barcelona, Spain